- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
BMP3 Antibody (C-term)Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP17009b | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
| AP17009b-ev20 | Ev20 size 100 ul | In Stock | $ 95.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
BMP3 Antibody (C-term) - Product info | |
| Application | WB
|
| Primary Accession | P12645 |
| Other Accession | NP_001192.2 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 53372 Da |
BMP3 Antibody (C-term) - Additional info | |
| Gene ID 651 | |
| Other Names BMP3; BMP3A; Bone morphogenetic protein 3; Bone morphogenetic protein 3A; Osteogenin | |
| Target/Specificity This BMP3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 317-347 amino acids from the C-terminal region of human BMP3. | |
| Dilution WB~~1:100~500WB~~1:1000 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions BMP3 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
BMP3 Antibody (C-term) - Protein Information | |
| Name BMP3 | |
| Synonyms BMP3A | |
| Function Negatively regulates bone density. Antagonizes the ability of certain osteogenic BMPs to induce osteoprogenitor differentitation and ossification | |
| Cellular Location Secreted. | |
| Tissue Location Expressed in adult and fetal cartilage. | |
BMP3 Antibody (C-term) - Related products
AP17009b: BMP3 Antibody (C-term)
AP1714a: Bmp3 Antibody (N-term)
DC09071: Human BMP3 cDNA Clone
BMP3 Antibody (C-term) - Application data
-
BMP3 Antibody (C-term) (Cat. #AP17009b) western blot analysis in ZR-75-1 cell line lysates (35ug/lane).This demonstrates the BMP3 antibody detected the BMP3 protein (arrow).
BMP3 Antibody (C-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
BMP3 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein, also known as osteogenin, induces bone formation.
REFERENCES
Stewart, A., et al. J. Cell. Physiol. 223(3):658-666(2010) Chen, X.R., et al. World J. Gastroenterol. 16(11):1409-1413(2010) Wu, D.D., et al. PLoS ONE 5 (6), E10959 (2010) : Yerges, L.M., et al. J. Bone Miner. Res. 24(12):2039-2049(2009) Gudbjartsson, D.F., et al. Nat. Genet. 40(5):609-615(2008)
